Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.

Medicenna Therapeutics Corp. ("Medicenna” or the "Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy co ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...